Cover Image

Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells

Aerobic glycolysis, discovered by Otto Warburg, is a hallmark of cancer metabolism even though not yet fully understood. The low activity of the cancerous pyruvate kinase isozyme (M2) is thought to play an important role by facilitating the conversion of glycolytic intermediates to other anabolic pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Almouhanna, Fadi (Author) , Blagojević, Biljana (Author) , Can, Suzan (Author) , Ghanem, Ali (Author) , Wölfl, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 22 January 2021
In: Cancer & metabolism
Year: 2021, Volume: 9, Issue: 1
ISSN:2049-3002
DOI:10.1186/s40170-021-00239-8
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s40170-021-00239-8
Verlag, kostenfrei, Volltext: https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-021-00239-8
Get full text
Author Notes:Fadi Almouhanna, Biljana Blagojevic, Suzan Can, Ali Ghanem and Stefan Wölfl
Description
Summary:Aerobic glycolysis, discovered by Otto Warburg, is a hallmark of cancer metabolism even though not yet fully understood. The low activity of the cancerous pyruvate kinase isozyme (M2) is thought to play an important role by facilitating the conversion of glycolytic intermediates to other anabolic pathways to support tumors’ high proliferation rate.
Item Description:Gesehen am 23.02.2021
Physical Description:Online Resource
ISSN:2049-3002
DOI:10.1186/s40170-021-00239-8

Similar Items